What is the percentage increase in plasma MDMA concentration when co-administered with bupropion?

MDMA-Bupropion Drug Interaction: 23% Increase in Plasma MDMA Concentration

Co-administration of bupropion with MDMA results in approximately a 23% increase in plasma MDMA concentrations. This clinically significant pharmacokinetic interaction occurs because bupropion inhibits the dopamine and norepinephrine transporters through which MDMA is metabolized 1.

Mechanism and Clinical Implications

The interaction is bidirectional and pharmacologically complex:

• Bupropion increases MDMA exposure by ~23% and prolongs MDMA's subjective effects 1
• MDMA reciprocally increases bupropion plasma concentrations 1
• Bupropion paradoxically reduces MDMA's cardiostimulant effects (lower heart rate elevation and norepinephrine release) despite increasing MDMA blood levels 1
• The mood-enhancing effects of MDMA are enhanced when combined with bupropion 1

This creates a dangerous clinical scenario: patients experience stronger and longer-lasting psychotropic effects while having higher plasma concentrations of both drugs 1.

Critical Safety Considerations

Contraindications and Warnings

Bupropion carries specific contraindications highly relevant to MDMA co-use:

• Seizure risk increases dose-dependently with bupropion, with baseline incidence of 0.1-0.4% at therapeutic doses 2
• Risk increases nearly 10-fold between 450-600 mg/day 2
• MDMA itself is a strong CYP2D6 inhibitor 3, 4, which can further elevate bupropion levels
• Illicit stimulant use (including MDMA) is specifically listed as a seizure risk factor with bupropion 2

Cardiovascular Concerns

While bupropion paradoxically reduces MDMA's acute cardiac stimulation 1, this should not be interpreted as protective:

• Bupropion causes treatment-emergent hypertension (2-6% incidence depending on formulation) 2
• Blood pressure monitoring is specifically recommended when bupropion is combined with other stimulants 2
• The combination produces elevated plasma concentrations of both drugs with unpredictable cumulative cardiovascular effects 1

Clinical Recommendations

Patients taking bupropion (for depression, smoking cessation, or ADHD) should be explicitly counseled to avoid MDMA use due to:

1. 23% increase in MDMA plasma levels leading to enhanced toxicity risk 1
2. Prolonged subjective effects increasing exposure duration 1
3. Elevated bupropion concentrations increasing seizure risk 1
4. Unpredictable cardiovascular effects from dual stimulant exposure 2, 1

For Patients Presenting with Acute Co-Ingestion

• Anticipate longer duration of MDMA effects than typical 4-6 hour window
• Monitor for seizure activity given compounded risk from both agents 2
• Assess for hypertensive crisis despite potentially blunted heart rate response 2
• Consider that standard MDMA toxicity timelines may be extended

Prescribing Context

When prescribing bupropion for any indication (depression 2, smoking cessation 5, ADHD 6, or obesity 7, 8, 9, 10), screen for recreational drug use patterns. The maximum recommended bupropion dose is 450 mg/day 2, but even therapeutic doses pose interaction risks with MDMA 1.

The 23% increase in MDMA plasma concentration represents a clinically meaningful pharmacokinetic interaction that substantially increases toxicity risk and should preclude concurrent use.